Multiple Sclerosis News Today

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia |Benjamin Hofmeister |Marisa Wexler

Biostate AI is partnering with the nonprofit Accelerated Cure Project (ACP) to develop a series of artificial intelligence (AI) models that can predict multiple sclerosis (MS) progression and how patients may respond to treatment. As part of the partnership, Biostate AI will use its high-throughput technology to profile RNA reads from ACP’s large collection of MS patient samples. RNA reads can be used as a measure of how active different genes are.

1 week ago | multiplesclerosisnewstoday.com | Steve Bryson |Margarida Maia |Andrea Lobo |Leigh Nelson

A single 600 mg dose of Briumvi (ublituximab-xiiy) — instead of the approved 150 mg initial dose plus a 450 mg dose two weeks later — was well tolerated by adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from the ENHANCE Phase 3b clinical trial (NCT05877963), which is evaluating the safety and efficacy of a modified treatment regimen of Briumvi.

1 week ago | multiplesclerosisnewstoday.com | Leigh Nelson |Patricia Inacio |Lindsey Shapiro

In recent months, I’ve attended a couple events in large stadiums. Last December, I went to the Music City Bowl college football game in Nashville, Tennessee, where Mizzou (the University of Missouri) beat the Iowa Hawkeyes. I also saw a Justin Timberlake concert at the T-Mobile Center in Kansas City, Missouri. Both events were great experiences for my family — except for my fear of falling.

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia |Lindsey Shapiro |Benjamin Hofmeister |Marisa Wexler

Frexalimab, an experimental antibody-based medication, was well tolerated and maintained disease control over two years in adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from an open-label extension to a Phase 2 clinical trial (NCT04879628) in which frexalimab outperformed a placebo at reducing the number of active and new or enlarging brain lesions in adults with relapsing-remitting MS or active secondary progressive MS (SPMS) after 12 weeks.

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary progressive multiple sclerosis (SPMS). That’s according to recently published data from the HERCULES Phase 3 trial (NCT04411641), where the experimental therapy also increased the odds of six-month confirmed disability improvement by 88%, and reduced the rate of new or enlarging lesions on MRI scans by 38%.